  Citation: Shah, M.A.; Udrea, A.A.; Bondarenko, I.; Mansoor, W.; Sánchez, R.G.; Sarosiek, T.; Bozzarelli, S.; Schenker, M.; Gomez-Martin, C.; Morgan, C.; et al. Evaluating Alternative Ramucirumab Doses as a Single Agent or with Paclitaxel in Second-Line Treatment of Locally Advanced or Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma: Results from Two Randomized, Open-Label, Phase II Studies. Cancers 2022, 14, 1168. https://doi.org/10.3390/ cancers14051168 Academic Editor: Kazuya Shinmura Received: 23 December 2021 Accepted: 5 February 2022 Published: 24 February 2022 Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affil- iations. Copyright: © 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https:// creativecommons.org/licenses/by/ 4.0/). cancers Article Evaluating Alternative Ramucirumab Doses as a Single Agent or with Paclitaxel in Second-Line Treatment of Locally Advanced or Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma: Results from Two Randomized, Open-Label, Phase II Studies Manish A. Shah 1, * ,† , Anghel Adrian Udrea 2 , Igor Bondarenko 3 , Was Mansoor 4 , Raquel Guardeño Sánchez 5 , Tomasz Sarosiek 6 , Silvia Bozzarelli 7 , Michael Schenker 8,9 , Carlos Gomez-Martin 10 , Carys Morgan 11 , Mustafa Özgüro ˘ glu 12 , Joanna Pikiel 13 , Haralabos P. Kalofonos 14 , Elzbieta Wojcik 15 , Tomas Buchler 16 , Daniel Swinson 17 , Irfan Cicin 18 , Mano Joseph 19 , Ihor Vynnychenko 20 , Alexander Valerievich Luft 21 , Peter C. Enzinger 22 , Tomas Salek 23 , Christos Papandreou 24 , Christophe Tournigand 25 , Evaristo Maiello 26 , Ran Wei 27 , David Ferry 28 , Ling Gao 28 , Joana M. Oliveira 28 and Jaffer A. Ajani 29,† 1 Department of Medicine, Division of Hematology and Medical Oncology, Weill Cornell Medical College, New York, NY 10021, USA 2 Cancer Center, Medisprof SRL, 400641 Cluj-Napoca, Romania; adrianudrea@medisprof.ro 3 Department of Oncology, Dnipropetrovsk Medical Academy, 49044 Dnipropetrovsk, Ukraine; igor.bondarenko@rdp-ukraine.com 4 Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester M20 4BX, UK; was.mansoor@christie.nhs.uk 5 Department of Medical Oncology, Catalan Institute of Oncology (ICO) Girona Hospital Dr Josep Trueta, 17007 Girona, Spain; rguardeno@iconcologia.net 6 Department of Clinical Oncology and Oncological Surgery, LUXMED Onkologia, 04125 Warszawa, Poland; tomasz.sarosiek@luxmed.pl 7 Medical Oncology and Hematology Unit, Humanitas Cancer Center, IRCCS Humanitas Research Hospital, 20089 Milan, Italy; silvia.bozzarelli@cancercenter.humanitas.it 8 Centrul de Oncologie Sf. Nectarie SRL, 200542 Craiova, Romania; michael.schenker@umfcv.ro 9 Department of Medical Oncology, University of Medicine and Pharmacy Craiova, 200342 Craiova, Romania 10 Medical Oncology Department, Hospital Universitario 12 de Octubre, 28041 Madrid, Spain; cgomezm@seom.org 11 Department of Clinical Oncology, Velindre Cancer Centre, Cardiff CF14 2TL, UK; carys.morgan6@wales.nhs.uk 12 Medical Oncology, Istanbul University, Cerrahpa¸ sa, Fatih, Istanbul 34098, Turkey; mozgur@iuc.edu 13 Department of Oncology, Copernicus Podmiot Leczniczy, 80-803 Gda´ nsk, Poland; joanna.pikiel@post.pl 14 Department of Oncology, University General Hospital of Patras Rion, 26504 Patras, Greece; kalofonos@upatras.gr 15 NZOZ Centrum Medyczne HCP, 62-030 Lubo´ n, Poland; onkologia.hcp@onet.eu 16 Department of Oncology, First Faculty of Medicine, Charles University and Thomayer University Hospital, 14059 Prague, Czech Republic; tomas.buchler@ftn.cz 17 Institute of Oncology, St James’s University Hospital, Leeds LS9 7TF, UK; daniel.swinson@nhs.net 18 Medical Oncology, Trakya University, Edirne 22030, Turkey; irfancicin@trakya.edu.tr 19 Deanesly Centre, New Cross Hospital, Wolverhamptom WV10 0QP, UK; mano.joseph@nhs.net 20 Sumy Regional Oncology Center, Sumy State University, 40000 Sumy, Ukraine; i.vynnychenko@med.sumdu.edu.ua 21 Department of Oncology No 1 (Thoracic Surgery), Leningrad Regional Clinical Hospital, 194291 St. Petersburg, Russia; alexander_luft@mail.ru 22 Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; peter_enzinger@dfci.harvard.edu 23 Department of Clinical Oncology, Narodny Onkologicky Ustav, 83310 Bratislava, Slovakia; tomas.salek@nou.sk 24 Department of Medical Oncology, Faculty of Medicine, University of Thessaly, Biopolis, 41223 Larissa, Greece; cpapandr@otenet.gr 25 Department of Medical Oncology, Henri Mondor et Albert Chenevier Teaching Hospital, Assistance Publique-Hôpitaux de Paris, University of Paris-Est Creteil, 94000 Créteil, France; christophe.tournigand@aphp.fr Cancers 2022, 14, 1168. https://doi.org/10.3390/cancers14051168 https://www.mdpi.com/journal/cancers